

Roche gains access to Cerep's proprietary BioPrint™ database and technology

Rueil-Malmaison, France, October 2, 2002 – Press release 2002/9

Cerep today announced the signature of a scientific agreement with Roche.

Under the terms of the agreement, Cerep will provide Roche with part of its proprietary BioPrint™ database and use on behalf of Roche, BioPrint™ tools. As part of the collaboration, Cerep will also profile Roche compounds in a panel of *in vitro* biological assays.
Financial terms were not disclosed.

"Roche will utilize aspects of Cerep's proprietary BioPrint™ database and derived knowledge to enhance fundamental understanding of the relationships between chemical structure and *in vitro* biological activity" commented Dr. Hans-Joachim Böhm, Head of Discovery Chemistry, from Roche, Basel (Switzerland).

"We are very proud of the recognition by Roche of the value of our *in silico* effort to improve drug discovery through BioPrint™ database and informatics tools" commented Thierry Jean, Chairman and CEO of Cerep.

Cerep's mission is to build a pipeline of drug candidates aimed to be licensed out at the beginning of clinical phases. The drug discovery effort is financed through profitable fee for services activities.

Cerep provides solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep's integrated platform encompasses a complete range of technologies including chemistry, biology, and informatics.

Cerep's technologies benefit to more than 200 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

Cerep's drugs pipeline includes collaborative drug candidates developed with Bristol-Myers Squibb, Sanofi-Synthélabo and Sepracor, as well as products discovered on its own.

Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the company's Document de référence.

Contact

Thierry Jean, President and CEO

Tel : + (33) 1 55 94 84 00

fincom@cerep.fr

Code Euroclear France : 6179 – Nouveau Marché

► **Thierry Jean, Chairman and CEO of Cerep, will speak at the UBS Warburg Global Life Sciences Conference on October 8 in New York City.**

The public is welcome to participate in the conference through an audio webcast on the UBS Warburg website. The audio transmission will be available live (8:00 am local time ; 12:00 am GMT ; 2:00 pm Paris time) and by replay. The replay will begin 3 hours after presentation time and will be available until November 10, 2002.

To access the audio webcast, go to www.ubswarburg.com ; find the UBS Warburg Conferences link in the lower right hand side of the page ; click on link. Follow link to Live Audio under the Global Life Sciences Conference heading.